PO-1204 Adjuvant immunotherapy after concurrent chemoradiotherapy for stage 3 NSCLC, outcomes from a large cancer centre. (August 2021) - Sun, F.; Mason, H.; Franks, K.; Teo, M.; Dickinson, P.; Clarke, K.; Jain, P.